Kyverna Therapeutics, Inc.KYTXNASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending lower, below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-116.45M
↓ 103% below average
Average (3y)
$-57.45M
Historical baseline
Range
High:$-23.44M
Low:$-116.45M
CAGR
+70.6%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-116.45M | -119.6% |
| 2023 | $-53.03M | -43.8% |
| 2022 | $-36.88M | -57.3% |
| 2021 | $-23.44M | - |